FDA issues complete response letter to Sobi’s NASP for gout
The FDA did not identify concerns about the clinical efficacy or safety of NASP that would affect its potential for approval.
Drug Development
Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe
Immunai and Boehringer partner to identify T-cell targets
Ionis grants Recordati rights to zilganersen for Alexander disease
MSD’s Keytruda-Padcev combo secures EC approval for MIBC
RQ Bio secures $115m to develop influenza antibody programme
Boehringer and Combotope partner for cancer antibodies
Haisco and Nuvectis sign licensing deal for two drugs
